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ABSTRACT Culture of Drosophila expressing the steroid-dependent GeneSwitch transcriptional activator
under the control of the ubiquitous a-tubulin promoter was found to produce extensive pupal lethality, as
well as a range of dysmorphic adult phenotypes, in the presence of high concentrations of the inducing
drug RU486. Prominent among these was cleft thorax, seen previously in ﬂies bearing mutant alleles of the
nuclear receptor Ultraspiracle and many other mutants, as well as notched wings, leg malformations, and
bristle abnormalities. Neither the a-tubulin-GeneSwitch driver nor the inducing drug on their own produced
any of these effects. A second GeneSwitch driver, under the control of the daughterless promoter, which
gave much lower and more tissue-restricted transgene expression, exhibited only mild bristle abnormalities
in the presence of high levels of RU486. Coexpression of the alternative oxidase (AOX) from Ciona intestinalis
produced a substantial shift in the developmental outcome toward a wild-type phenotype, which was depen-
dent on the AOX expression level. Neither an enzymatically inactivated variant of AOX, nor GFP, or the
alternative NADH dehydrogenase Ndi1 from yeast gave any such rescue. Users of the GeneSwitch system
should be aware of the potential confounding effects of its application in developmental studies.
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TheGeneSwitch (GS) system is commonlyused toactivate transgenes in
Drosophila in a graded fashion. GS comprises a modiﬁed form of the
yeast transcriptional activator Gal4, which is covalently linked to the
hormone-binding fragment of the progesterone receptor, rendering its
transcriptional activity dependent on an exogenously supplied proges-
terone analog, RU486 or mifepristone (Osterwalder et al. 2001). Any
transgene governed by the UAS promoter element, rendering it Gal4-
responsive, may be induced by the combination of GS and RU486 in a
dose-dependent manner. Depending on the promoter to which GS is
itself combined, plus its insertion site in the ﬂy genome, drug-inducible
transgene expression can be achieved in a wide variety of developmen-
tal patterns, cell-types, and overall strengths. Thus, the widely used
a-tubulin-GS (tubGS) and actin5C-GS drivers confer ubiquitous,
RU486-dependent transgene expression when crossed to lines bearing
a UAS-governed transgene. Tissue-speciﬁc drivers such as the neuron-
speciﬁc elav-GS enable transgene expression in just one tissue, but again
at a level and timing that can bemanipulated over a wide range. The use
of this system is predicated on the assumption that the expression of
GeneSwitch and exposure to RU486 do not themselves produce mea-
surable effects on ﬂy physiology and development, which is supported
by controls in many studies.
Our laboratoryhasmadeuseof this system, for example toexpress, in
Drosophila, foreign transgenes coding for nonproton-motive alterna-
tive respiratory chain enzymes derived from simpler eukaryotes, such
as the alternative oxidase (AOX) from Ciona intestinalis (Fernandez-
Ayala et al. 2009; Kemppainen et al. 2014a). When supplied to adult
Drosophila bearing both tubGS and a UAS-AOX transgene, RU486
produced dose-dependent transgene expression that saturated at drug
concentrations (in ﬂy food) of 100–200mM (Kemppainen et al. 2014a).
However, when supplied throughout development, RU486 concentra-
tions two orders of magnitude lower were sufﬁcient to induce maximal
expression (Fernandez-Ayala et al. 2009). The precise reasons for this
discrepancy in required dose are unclear, although early larvae, which
are very rapidly growing (Church and Robertson 1966; Watts et al.
2006), must absorb larger amounts of drugs added to ﬂy food than
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adults, which do not grow at all and even lose weight during early adult
life (Fernandez-Ayala et al. 2009).
In this study, we addressed the issue of what happens to devel-
opment when larvae expressing GeneSwitch drivers (but no other
transgene) are exposed to RU486 concentrations in excess of those
sufﬁcient to produce maximal transgene expression. We detected a
variety of developmental abnormalities dependent on driver expres-
sion and drug dose. Surprisingly, expression of AOX, but not other
transgenes such as GFP or the yeast alternative NADH dehydroge-
nase Ndi1, mitigated these effects.
MATERIALS AND METHODS
Drosophila stocks and maintenance
Wild-type (Oregon R), standard transgenic host strainsw1118 andwDAH
(Dahomey) and the UAS-GFP (Stinger) line (insertion on chromosome
2) were obtained from stock centers. The tubGS driver line with inser-
tion on chromosome 3 (Sykiotis and Bohmann 2008) was a kind gift
from Dr Scott Pletcher (University of Michigan). The daughterless-GS
(daGS) line (Tricoire et al. 2009) was a kind gift from Dr Alberto Sanz
(Newcastle University, UK). AOX andNdi1 transgenic ﬂies [linesUAS-
AOXF6, UAS-AOXF24, tub-AOX7, tub-AOX35 tub-AOX50, UAS-AOX7.1
(targeted insertion on chromosome 3) UAS-AOXmut (denoted previ-
ously as UAS-AOX4.1, targeted insertion on chromosome 3), and UAS-
Ndi1B20] were as described previously (Fernandez-Ayala et al. 2009;
Sanz et al. 2010b; Kemppainen et al. 2014b; Andjelkovic et al. 2015).
Flies were maintained in standard high-sugar medium (Fernandez-
Ayala et al. 2009) at 25, on a 12 hr light/dark cycle. Where indicated,
medium was supplemented with RU486 (Mifepristone, Sigma) at the
concentrations indicated in ﬁgures and legends.
Eclosion and phenotypic assays
Crosses were conducted in a minimum of three, usually four to ﬁve
replicates, as described previously (Toivonen et al. 2001; Kemppainen
et al. 2009). Either the number of ﬂies eclosing or the percentage of
pupae that successfully eclosed in individual vials were recorded in
different experiments (see ﬁgures and legends). The proportion of
the eclosed progeny falling into different phenotypic classes was scored
by microscopy. Cleft thorax, where subclassiﬁed, was scored as mild or
severe (heminota clearly separated), with the mildest abnormality, mal-
formed scutellum, scored separately in some experiments. Wing phe-
notypes were scored as normal or notched, the latter ranging from
single notches to grossly malformed wings that in some cases did not
inﬂate properly. Flies showing any of the bristle abnormalities as de-
scribed below were generally scored as a single category.
Microscopy
Light microscopy images of eclosed adult ﬂies were taken with a Nikon
Digital DS-Fi1 High-Deﬁnition Color Camera, using the Nikon stereo-
scopic zoom microscope SMZ 745T run by NIS-Elements D 4.20
software. Fluorescence microscopy of ﬂies used a Zeiss Axio Imager
2 microscope (50 ·magniﬁcation). Z projection images were generated
using Carl Zeiss Zen 2012 software.
Protein analysis by western blotting
Total protein was extracted from batches of 20 pupae crushed in
homogenization buffer, and processed as described previously
(Andjelkovic et al. 2015). Primary antibodies used were customized
rabbit anti-AOX (Fernandez-Ayala et al. 2009; 21st Centrury Biochem-
icals, 1:10,000), and mouse anti-ATP5A (Abcam, 1:100,000), with sec-
ondary antibodies as described previously (Andjelkovic et al. 2015).
Data availability
The authors state that all data necessary for conﬁrming the conclusions
presented in the article are represented fully within the article.
RESULTS
tubGS plus high levels of RU486 produce
developmental abnormalities
In initial trials, we noticed that doses of RU486 used routinely to induce
UAS-dependent transgene expression in Drosophila, in combination
with the tubGS driver in adult ﬂies (200–500 mM; Kemppainen et al.
2014a), were lethal when present throughout development. In order to
investigate possible mechanisms of this lethality, we reared ﬂies at
RU486 doses intermediate between this lethal level, and levels sufﬁcient
to induce full dose-dependent transgene expression, which in larvae
was only 1–2 mM. In combination with tubGS, RU486 at 100 mM was
still lethal (Figure 1A), whereas tubGS ﬂies reared without drug,
or wild-type ﬂies reared at this concentration of RU486, developed
normally. At intermediate drug concentrations (5–50 mM, Figure 1,
A and B), we observed dose-dependent semilethality, althoughmany of
the eclosing ﬂies were very weak and died within 1 d. In addition, even
the viable ﬂies displayed a range of dysmorphic phenotypes, illustrated
in Figure 2 and Supplemental Material, Figure S1 and File S1, of which
the commonest andmost striking were cleft thorax (Figure 2, B–D) and
notched wings (Figure 2E). The observed phenotypes were of varying
severity. For example, some ﬂies had single or multiple notches at the
wingmargin (Figure 2E), whereas others had wings that failed to inﬂate
(Figure 2F). Cleft thorax ranged from severe, with the heminota com-
pletely separated (Figure 2, C and D), to very mild, showing only an
abnormal, parted bristle pattern or just a reduced scutellum (Figure
2A). A minority of ﬂies also showed necrotic tissue in the notum area
(Figure 2D), leg abnormalities such as overgrown, reduced, and fused
leg segments (Figure 2G), externalized trachea (Figure 2H), clefted
abdomen (Figure 2I), or a variety of malformations of macrochaetae
(supernumerary, missing, kinked, or short bristles, Figure S1). Clefting
also extended along the abdomen in some cases (Figure 2I). tubGS ﬂies
reared without drug, or cultured in RU486 in the absence of tubGS, did
not exhibit cleft thorax or other developmental abnormalities, indicat-
ing that these teratogenic effects require the combination of the mod-
iﬁed transcription factor plus the inducing steroid.
We quantiﬁed themain classes of abnormality and observed a dose-
dependence on RU486 (Figure 3A). Although the proportion of prog-
eny showing the two major dysmorphic phenotypes of cleft thorax or
notched wings was already substantial at 10mMRU486, increasing the
dose to 30 mM resulted in a signiﬁcant increase in the proportion
exhibiting cleft thorax, whereas a further increase to 50 mM produced
a signiﬁcantly greater proportion with notched wings.
In order to determine whether the induction of these developmental
defects was a general property of GeneSwitch drivers, or a phenome-
non speciﬁc to tubGS, we repeated the experiment using a second
GeneSwitch driver under the control of the daughterless promoter. In
contrast to tubGS, daGS in combination with 10 mM RU486 produced
no clefting and no wing defects. The only developmental abnormality
detected was in regard to bristle morphology and organization which,
while less frequently observed than with the tubGS driver, did show a
tendency to rise in frequency as the concentration of RU486 was in-
creased (Figure 3C). However, neither cleft thorax nor notched wings
were seen at these elevated drug concentrations, nor even at 100 mM.
The difference in the ﬁndings between the two drivers is most likely
attributable to the level and pattern of expression of the GeneSwitch
transcription factor, as reﬂected in its ability to drive transgene
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expression, which we proﬁled quantitatively by western blotting
using a UAS-AOX reporter (Figure S2A) and spatially using a
UAS-GFP reporter (Figure S2B). Expression of UAS-AOX driven
by daGS was quantitatively much less than when driven by tubGS,
even at high RU486 concentrations (Figure S2A). Furthermore, un-
like tubGS, which was able to drive expression ubiquitously in the
developing larva, daGS produced transgene expression only in
a minority of cells (Figure S2B), including salivary glands, parts of
the trachea, some epithelial cells, and segmentally reiterated cell
clusters.
Expression of AOX, but not Ndi1 or GFP, rescues cleft
thorax caused by tubGS/RU486
Wetestedwhetherconcomitantexpressionofother transgenesdrivenby
tubGS in the presence of RU486 was able to modify the developmental
phenotypes resulting from the driver and drug alone (Figure 4). Once
again, neither tubGS nor the drug on its own produced cleft thorax
(Figure 4A) but, when combined, over 50% of the eclosing progeny
manifested severe cleft thorax, and a further 20% showed mild clefting.
Coexpression of Ciona AOX from either of two UAS-AOX transgenic
lines (Fernandez-Ayala et al. 2009) produced a substantial rescue of the
phenotype, with over 50% of the eclosing progeny now showing no
cleft, and less than 20% having severe cleft. UAS-Ndi1 or UAS-GFP
produced no rescue of the phenotype. Nor did a single copy of AOX,
when constitutively expressed under the a-tubulin promoter at a much
lower level than when driven by tubGS (Kemppainen et al. 2015).
However, ﬁve copies of the tub-AOX transgene, when present simul-
taneously, did produce a rescue comparable with that of UAS-AOX.
Coexpression of UAS-AOX with tubGS plus drug, in either of two
backgrounds commonly used in transgenic studies (w1118 and wDAH)
also increased the proportion of pupae eclosing (Figure 4B). The si-
multaneous presence of ﬁve tub-AOX transgenes (Figure 4C) also sub-
stantially rescued the eclosion frequency, as well as the survival of adults
immediately after eclosion.
Figure 1 RU486 in combination with tubGS pro-
duces dose-dependent lethality. (A) Number of
tubGS progeny eclosing at different doses of
RU486 present throughout development, mean 6
SD per vial, in OregonR background. Note that at
100 mM, no ﬂies eclosed.  and # indicate signiﬁ-
cant differences from the next higher concentration
tested in pairwise comparisons (Student’s t-test, P,
0.01 and 0.05, respectively). (B) Proportion (% of
pupae formed) of tubGS progeny at different doses
of RU486 present throughout development; com-
bined data from sets of four vials at a given concen-
tration, set up in parallel, in w1118 background. n =
205 (at 5 M), 193 (at 7.5 mM), 210 (at 10 mM), and
146 (at 12.5 mM). tubGS plus RU486 produced com-
parable amounts of pupal lethality also in the Can-
tonS background. SD, standard deviation; tubGS;
a-tubulin-GeneSwitch.
Figure 2 Examples of dysmorphologies produced by
the tubGS driver in the presence of 10 mM RU486.
(A–D) Thoracic abnormalities: (A) missing scutellar
part, (B) mild cleft, (C) severe cleft, and (D) necrotic
tissue, always localized at the scutellum or notum. (E
and F) Wing abnormalities: (E) notched wings, with
notches localized on the marginal anterior or posterior
side or both, (F) noninﬂated wings. (G) Leg abnormal-
ities, including overgrown, reduced, and fused leg
segments, sometimes present all together. (H) Exter-
nalized trachea, always in the ventral abdomen. (I)
Abdominal clefting: strong midline splits between all
dorsal tergite plates; laterotergites do not fuse at the
dorsal midline and remain as hemitergites, with in-
complete fusion of abdominal epidermis. These phe-
notypes were seen in all genetic backgrounds tested
(OregonR, CantonS, w1118, and wDAH). tubGS;
a-tubulin-GeneSwitch.
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AOX rescues developmental abnormalities in a
dose-dependent manner
We next conducted a large-scale experiment, analyzing almost 2000
individual ﬂies, for each of the major classes of developmental abnor-
mality produced by tubGS in the presence of RU486, in the presence of
different UAS-dependent transgenes (Figure 5). As negative control we
used strain w1118, the background strain for all the transgenic lines that
were crossed in the experiment. To determine whether the failure of
a single copy of tub-AOX to rescue tubGS-induced cleft thorax was
due to low expression, we made use of an additional UAS-AOX line,
Figure 3 Effects of drug con-
centration, driver, and genetic
background on developmental
abnormalities induced by Gen-
eSwitch plus RU486. (A) Propor-
tion of viable adult progeny
exhibiting major phenotypic ab-
normalities as indicated, at dif-
ferent doses of RU486, in the
Oregon R genetic background.
Mean 6 SD for sets of n $ 4 in-
dependent vials. Horizontal bars
denote signiﬁcant differences for
a given phenotypic trait be-
tween the stated drug concen-
trations (Student’s t-test, P ,
0.05). (B) Proportion of progeny
in different phenotypic classes of
tubGS ﬂies in the w1118 and
wDAH backgrounds grown at
10 mM RU486. Note that the
adult phenotypes are scored as
percentages of the viable adult
ﬂies that eclosed. Total numbers of pupae analyzed in each large-scale experiment (n) as indicated. (C) Proportion of adult progeny showing
bristle abnormalities, as illustrated in Figure S1, in ﬂies grown at the indicated doses of RU486, bearing the tubGS or daGS drivers as indicated.
Large-scale experiment using the daGS driver analyzed n = 508 individual adult ﬂies (10 mM), n = 758 (30 mM), and n = 246 (50 mM). The data for
the tubGS driver at 10 mM is the mean6 SD for three independent experiments (n = 89, 284, and 157 adults analyzed). See also Figure S2. daGS,
daughterless-GeneSwitch; SD, standard deviation; tubGS; a-tubulin-GeneSwitch.
Figure 4 AOX partially rescues
cleft thorax and developmental
lethality of tubGS/RU486. Propor-
tion of adult progeny exhibiting
the indicated phenotypes, with
hemizygous transgenes as indi-
cated, cultured with (+) or without
(–) 10 mM RU486. n $ 3 replicate
vials for each genotype studied
(except UAS-Ndi, n = 2, hence
no error bars shown). Transgenic
lines containing tub-AOX trans-
genes (Kemppainen et al. 2014)
had either a single hemizygous
copy or else ﬁve copies (two ho-
mozygous, plus hemizygous copy
on chromosome 3, combined
with tubGS on the same chro-
mosome).  denotes data classes
signiﬁcantly different from the
equivalent class for control lack-
ing any transgene additional to
tubGS (Student’s t-test with Bon-
ferroni correction, P , 0.01). (B) Proportion of pupae from two different genetic backgrounds (bkd), as shown, eclosing after culture in 10 mM
RU486. All pupae carried the tubGS driver and either no other transgene, or either of two different UAS-AOX transgenes, as indicated. # and 
denote data classes signiﬁcantly different from nontransgenic ﬂies in the same genetic background (Student’s t-test, P , 0.05 or 0.01, re-
spectively). (C) Proportion of pupae eclosing as viable or nonviable adults after culture in 10 mM RU486. All pupae carried the tubGS driver
and either no other transgene, or else ﬁve copies of tub-AOX transgenes (see above). Nonviable adults were those that died on the day of
eclosion.  denotes phenotypic classes of transgenic ﬂies signiﬁcantly different from corresponding class of nontransgenic ﬂies (Student’s t-test,
P , 0.01). AOX, alternative oxidase; GFP, green ﬂuorescent protein; tubGS; a-tubulin-GeneSwitch.
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UAS-AOX7.1 (Andjelkovic et al. 2015), showing much lower expression
than either ofUAS-AOXF6 orUAS-AOXF24. Finally, to conﬁrm that the
enzymatic activity of AOX is required for the rescue, we also included a
line (UAS-AOXmut) expressing a catalytically inactive variant of AOX
(Andjelkovic et al. 2015). The proportion of abnormal phenotypes
obtained using UAS-AOXmut was virtually indistinguishable from the
background strain w1118, while the weakly expressing UAS-AOX7.1
transgene produced an intermediate spectrum of phenotypes, with cleft
thorax, leg, and bristle abnormalities signiﬁcantly improved over the
background strain, but to a much lower extent than seen with the
strongly expressing lines UAS-AOXF6 and UAS-AOXF24. UAS-AOX7.1
also produced no rescue of the notched wings phenotype, while UAS-
Ndi1B20 signiﬁcantly exacerbated all of the abnormal phenotypes com-
pared with the background strain, with the exception of leg malformations,
which were decreased in frequency.
DISCUSSION
In this study, we identiﬁed a range of developmental abnormalities
associated with the use of the tubGS driver in combination with RU486.
These were seen at concentrations only slightly above those commonly
used to induce transgene expression inDrosophila during development.
At concentrations of 2.5 mM or above, we observed substantial pupal
lethality, while at 10 mM or above the majority of viable eclosed adults
had visible dysmorphic features, commonly including notched wings
and cleft thorax. Importantly, these phenotypes were dependent on
both the driver and the drug: neither alone produced any evidence of
developmental lethality or abnormality, and the effects did not appear
to be background dependent, since theywere seen inwild-typeOregonR
and Canton-S ﬂies, as well as in two white-eyed lines commonly used in
transgenic studies. A different GeneSwitch driver, with a much lower
and more restricted expression pattern, based on its ability to drive GFP
expression (Figure S2), produced only very subtle abnormalities in bris-
tle organization.
Mechanism of developmental disturbance
by tubGS/RU486
Previous authors have noted that RU486 treatment alone produces no
detectable abnormalphenotypes, althoughexpressionof a smallnumber
of mRNAs is altered in adults treated with the drug (Etter et al. 2005).
Given that we also saw no abnormalities from the use of tubGS or
RU486 on their own, we can exclude the possibility that RU486 binds
to or interferes with the activity of known nuclear receptors in Dro-
sophila (Fahrbach et al. 2012), or that the GeneSwitch transcription
factor is able to interact with any of their physiological ligands. How-
ever, ligand-bound GeneSwitch may be able to interact either with one
or more of these receptors, its targets, or other regulatory factors in-
volved in developmental patterning; for example, by the formation of
nonphysiological heterodimers between ligand-bound GeneSwitch and
bona ﬁde nuclear receptors.
The major dysmorphologies we observed have been reported pre-
viously in a variety ofmutants, often in combinations similar to those
that we observed. Cleft thorax has been reported in mutants of
Ultraspiracle (Henrich et al. 1994), a dimerization partner of the
ecdysone receptor and thus one of the key nuclear receptors regulat-
ing development progression in the ﬂy. It has also been reported in
mutants of the GATA transcription factor pannier (Heitzler et al.
1996) and the zinc-ﬁnger pair-rule transcription factor gene odd
(Tripura et al. 2011). Bristle abnormalities similar to those that we
observed are also characteristic of mutants of the dimerization part-
ner of pannier, u-shaped (Cubadda et al. 1997).
Mutants in the components of the AP-1 transcription factor, jun-
related antigen (homolog of mammalian c-Jun) and kayak (homolog of
mammalian c-Fos), as well as in the JNK signaling pathway that links
AP-1 activity to various upstream developmental signals, cause cleft
thorax (reviewed by Zeitlinger and Bohmann 1999; Kockel et al.
2001). Defects in JNK signaling also underlie wing defects and leg
malformations (Kirchner et al. 2007), and have been implicated in
midline closure defects in mammals (Chi et al. 2005; Zhu et al. 2016).
Cleft-thorax can result both from downregulation of effectors of JNK
signaling, such as the serine protease scarface (Srivastava and Dong
2015), or from mutations in receptor tyrosine kinase Pvr (Garlena
et al. 2015), an upstream JNK pathway activator (Ishimaru et al. 2004;
Igaki 2009). Thoracic closure also depends on downstream targets
such as proteins implicated in cytokinesis and cell adhesion (Sfregola
2014), as well as intracellular protein trafﬁcking (Thomas et al. 2009).
Mutants of blistery, encoding tensin, result in blistered wings, and
interact also with JNK signaling (Lee et al. 2003). Overexpression of
the inhibitor of matrix metalloproteases (Timp) results in pupal le-
thality and cleft thorax (Srivastava et al. 2007). Finally, wing disc-
speciﬁc knockdown of Tap42, a key regulator of protein phosphatases,
Figure 5 AOX rescues diverse
developmental abnormalities
produced by tubGS. Proportion
of progeny hemizygous for
both tubGS and the indicated
transgenes, which exhibited the
indicated developmental ab-
normalities, when reared on
food containing 10 mM RU486.
The total numbers of ﬂies of
each genotype analyzed, in a sin-
gle large-scale experiment (n), is
as shown. See supplemental
material for a detailed descrip-
tion of phenotypic categories.
Asterisks indicate signiﬁcant dif-
ferences (P , 0.001) from the
w1118 background strain hemizy-
gous for tubGS, based on chi-
squared analysis for each phenotypic category or for the four thoracic phenotypes (normal thorax, malformed scutellum, mild cleft, and severe
cleft) considered as a whole. AOX, alternative oxidase; tubGS; a-tubulin-GeneSwitch.
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gives rise to cleft thorax and to wing abnormalities similar to some
that we observed (Wang et al. 2012).
Notched wings are another previously observed phenotype in many
mutants, including those affecting the highly pleiotropic intercellular
signaling factor Notch (originally discovered by Morgan; Welshons
1958), SNARE-dependent membrane trafﬁcking (Stewart et al. 2001),
protein phosphatase PP2A (Kunttas-Tatli et al. 2009), the RNA-bind-
ing fragile X protein FMR1 (Wan et al. 2000), and histone deacetylation
(Pile et al. 2001).
The exact pattern of developmental abnormalities brought about by
GeneSwitch together with its ligand appears to reﬂect the tissue spec-
iﬁcity of its expression. Thus, whereas the widely expressed tubGS
produces a plethora of abnormal phenotypes, daGS, with much more
restricted larval expression (Figure S2), primarily in segmentally reit-
erated clusters of cells that might represent larval sense organs
(Brewster and Bodmer 1995), has only a single visible phenotype in
the adult, affecting the sensory bristles (Figure 3C). The use of other
GeneSwitch drivers may help to further clarify how its level and pattern
of expression affect the phenotypic outcome.
Finding a common thread through this rather bewildering array of
phenotypes and genetic pathwaysmay not be straightforward. However,
transcriptional cascades are considered to be the main determinants of
developmental processes, and the key system for regulating morpho-
genesis at pupal stage is the steroid hormone 20-hydroxyecdysone
(Riddiford 1993). Thus, an interference with ecdysteroid-dependent
transcription is the most parsimonious explanation for the pleiotropic
effects we observed, even thoughmolecular details remain to be ﬁlled in.
Mechanism of AOX rescue of developmental
disturbance by tubGS/RU486
While the observation that GeneSwitch-plus-RU486 can produce a
range of developmental abnormalities may be unexpected, their rescue
by a mitochondrially localized electron-transfer protein from another
phylum is even more surprising. It is important to note that, while the
abnormal phenotypes were produced by using an engineered (and thus
nonphysiological) transcription factor, andwere rescued by a gene from
a distant phylum, the effects were systematic in both cases, indicating
meaningful underlying biological processes. Thus, the extent of AOX
rescue of pupal lethality, cleft thorax, and other dysmorphologies was
dependenton theAOXexpression level, since strains expressingonlyata
low level (single-copy of constitutive tub-AOX, or low-expressor GAL4-
dependent lineUAS-AOX7.1) produced a less dramatic alleviation of the
phenotypes studied than the corresponding high-expressors (5 · tub-
AOX, UAS-AOXF24, and UAS-AOXF6). Rescue was dependent on the
enzymatic activity of AOX and was not seen with an inert reporter
protein (GFP) or a different mitochondrially localized electron-transfer
protein, yeast Ndi, which appeared to exacerbate some phenotypes.
AOX maintains ATP production, redox homeostasis, and metabolic
ﬂux under physiological conditions where respiratory complexes III
and IV are limiting due to overload, toxins, or genetic damage, and
concomitantly limits mitochondrial ROS production consequent upon
overreduction of the quinone pool (El-Khoury et al. 2014). AOX also
has an unexplained antioxidant effect, decreasing net mitochondrial
ROS output even under conditions where the respiratory chain is func-
tioning normally (Fernandez-Ayala et al. 2009; Sanz et al. 2010a).
How this links to a global alleviation of developmental perturbations
brought about by interference with transcriptional cascades or cell
signaling is far from clear. In a general sense, our ﬁndings hint at
a common metabolic regulation of transcription, such as evidenced
previously byAMPKsirtuins or PARP (Kraus and Lis 2003; Ghosh et al.
2010; Gut and Verdin 2013; Schiewer and Knudsen 2014; Salminen
et al. 2016), although none of these is obviously implicated, so a novel
pathwaymay be involved. Inmice, nuclear receptors are responsive to a
variety ofmetabolic effectors, which can also bemicrobiome-dependent
(Montagner et al. 2016), while cross-talk between nutrient-based sen-
sors and nuclear receptors is dependent on mitochondrial stress signals
and inﬂuences mitochondrial gene expression (Kang et al. 2015).
Many transcription factors, including nuclear receptors such as
LXRa (Serviddio et al. 2013) or NR4A1 (Shimizu et al. 2015) in mam-
mals, are known to be activated in response to oxidative stress
(Lavrovsky et al. 2000), and redox regulation of nuclear receptors such
as the glucocorticoid receptor (Tanaka et al. 1999) is well established.
AOX may therefore act by providing a general dampening of ROS,
normalizing developmental outcomes dependent on such receptors,
with which GeneSwitch plus RU486 interferes. An exhaustive study
using different ROS scavengers may shed further light on this.
Another possibility is based on the observation that synthesis of
20-hydroxyecdysone requires mitochondrial Fe-S cluster-containing
proteins dependent on frataxin (Palandri et al. 2015) and mitoferrin
(Llorens et al. 2015). Because Fe-S proteins are highly susceptible to
ROS damage, a general ROS dampening effect of AOXmay counteract
transcriptional interference from ligand-bound GeneSwitch, simply by
boosting endogenous ecdysteroid synthesis.
Recommendations on use of GeneSwitch drivers
The GeneSwitch system was originally elaborated using other drivers
than tubGS, i.e., those linked to the neuron- and muscle-speciﬁc elav
and Mhc promoters, respectively (Osterwalder et al. 2001), or for spe-
ciﬁc expression in other tissues such as the fat body (Roman et al. 2001).
Subsequently, the “ubiquitous”GS drivers (such as tubGS andActin5C-
GS) have been brought into use for inducing broad expression, both in
adults and larvae (Ford et al. 2007; Waskar et al. 2009; Wigby et al.
2011; Paik et al. 2012; Kuo et al. 2012; Kemppainen et al. 2014a,b; Sun
et al. 2014; Da-Rè et al. 2014).
Our work raises at least two concerns. First, the visible interference
with developmental processes at saturating or near-saturating drug
concentrations, using the tubGS driver, indicates the need for rigorous
controls and cautious interpretation of all data obtained using this
driver during development. Furthermore, we obviously cannot rule
out subtler but also biologically signiﬁcant effects that did not have
visible manifestations, even at lower drug concentrations than those
employed here. Second, other GeneSwitch drivers activated during de-
velopment may also be vulnerable to such effects, since our data indi-
cate that they depend on the drug and the transcription factor in
combination, which applies wherever they are colocated. An exam-
ple would be the recently published use of a GeneSwitch driver to
overexpress malic enzyme (Kim et al. 2015). The driver in this exam-
ple was originally reported to induce expression in the adult abdom-
inal fat body (Hwangbo et al. 2004), although Kim et al. (2015) found
that expression in larvae was instead driven in the salivary glands,
Malpighian tubule, and part of the gut. In this particular paper, the
appropriate controls without the transgene were indeed implemented
for the adult (see Supplementary Table 1C of Kim et al. 2015), but some
questions remain. The driver plus drug alone did not affect the body
weight of L3 larvae (Figure 3A of Kim et al. 2015), but effects on stress
resistance and lifespan in such controls were not documented. The
concentrations of RU486 used by Kim et al. (2015), i.e., 2.5–10 mg/ml,
corresponding with 5.8–23 mM, were within the range in which we saw
major developmental effects using the tubGS driver. Similarly, in
ﬂies expressing GeneSwitch in speciﬁc endocrine cells during
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development, using a customized driver and RU486 at even higher
concentrations from larval L2 stage onwards (Cho et al. 2014), clear
developmental abnormalities were attributed to knockdown of a nu-
clear receptor, although driver-plus-drug controls were not included
in all of the experiments reported. Some phenotypes observed (Figure 3
of Cho et al. 2014) resemble those that we report here (pupal lethality,
uninﬂated wings, abdominal clefting, and leg malformations). While
their interpretation that these are due to disrupted ecdysone signaling
may be correct, an effect of GeneSwitch plus RU486 in the target cells
cannot be excluded. Phenotypic rescue by injected ETH (Table 2 of
Cho et al. 2014) conﬁrmed the involvement of disrupted ecdysis, but
not the underlying causes thereof. A further possible example already
reported in the literature is the effect of the abdominal fat body-
speciﬁc GeneSwitch driver on lifespan, when RU486-containing food
was supplied in the adult to drive the supposedly inert GFP transgene
(Ren andHughes, 2014. RU486-dependent lethality in larvae containing
the Elav-GeneSwitch driver (Shen et al. 2009), and embryonic lethal-
ity produced by either the Elav- or Actin5C-GeneSwitch drivers plus
maternal RU486 (Landis et al. 2015), have been previously reported.
We would recommend that future users of all GeneSwitch drivers
should routinely include otherwise nontransgenic controls bearing the
drivers, plus and minus drug, in all experiments. Based on our ﬁndings
(Figure S2B), the daGS driver is clearly not ubiquitous, despite the fact
that the daughterless gene itself, as well as the “standard” daGAL4
drivers, do show widespread expression.
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